Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rezolute, Inc.

3.67
-0.0600-1.61%
Post-market: 3.810.1400+3.81%19:55 EDT
Volume:853.77K
Turnover:3.15M
Market Cap:313.73M
PE:-3.13
High:3.79
Open:3.73
Low:3.57
Close:3.73
Loading ...

Rezolute Inc - DMC Approves Infant Enrollment Into Double-Blind Study

THOMSON REUTERS
·
04 Feb

Rezolute Provides Update on Its Phase 3 Sunrize Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

THOMSON REUTERS
·
04 Feb

Rezolute Inc - Sunrize Enrollment Completion Expected in Q2 2025

THOMSON REUTERS
·
04 Feb

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

GlobeNewswire
·
04 Feb

Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia

MT Newswires Live
·
07 Jan

Rezolute receives BTD from FDA for ersodetug in treatment of hypoglycemia

TIPRANKS
·
07 Jan

BRIEF-Rezolute Receives Breakthrough Therapy Designation From FDA For Ersodetug In The Treatment Of Hypoglycemia Due To Congenital Hyperinsulinism

Reuters
·
07 Jan

Rezolute Inc: Topline Sunrize Data Expected Second Half of This Year

THOMSON REUTERS
·
07 Jan

Rezolute Receives Breakthrough Therapy Designation From FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

THOMSON REUTERS
·
07 Jan

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Zacks
·
24 Dec 2024

Rezolute reports inducement award under Nasdaq listing rule

TIPRANKS
·
05 Dec 2024

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Dec 2024

Sector Update: Health Care Stocks Higher Tuesday Afternoon

MT Newswires Live
·
04 Dec 2024

Rezolute Gets FDA Orphan Drug Designation for Ersodetug in Tumor Hyperinsulinism-Related Hypoglycemia

MT Newswires Live
·
03 Dec 2024

Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment

Dow Jones
·
03 Dec 2024

Rezolute announces U.S. FDA granted ODD to ersodetug

TIPRANKS
·
03 Dec 2024

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (Rz358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

THOMSON REUTERS
·
03 Dec 2024

Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies

TIPRANKS
·
26 Nov 2024

Rezolute granted FDA orphan designation for treatment of hypoglycemia

TIPRANKS
·
21 Nov 2024